- Home
- ACRV vs DXR Comparison
ACRV vs DXR Comparison
Compare ACRV & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- DXR
- Stock Information
- Founded
- ACRV 2018
- DXR 1970
- Country
- ACRV United States
- DXR United States
- Employees
- ACRV N/A
- DXR N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- DXR Medical/Dental Instruments
- Sector
- ACRV Health Care
- DXR Health Care
- Exchange
- ACRV Nasdaq
- DXR Nasdaq
- Market Cap
- ACRV 42.5M
- DXR 40.3M
- IPO Year
- ACRV 2022
- DXR N/A
- Fundamental
- Price
- ACRV $1.81
- DXR $7.41
- Analyst Decision
- ACRV Strong Buy
- DXR Strong Buy
- Analyst Count
- ACRV 6
- DXR 1
- Target Price
- ACRV $21.80
- DXR $25.00
- AVG Volume (30 Days)
- ACRV 412.6K
- DXR 5.1K
- Earning Date
- ACRV 05-13-2025
- DXR 01-01-0001
- Dividend Yield
- ACRV N/A
- DXR N/A
- EPS Growth
- ACRV N/A
- DXR 86.16
- EPS
- ACRV N/A
- DXR 0.11
- Revenue
- ACRV N/A
- DXR $119,714.00
- Revenue This Year
- ACRV N/A
- DXR N/A
- Revenue Next Year
- ACRV N/A
- DXR N/A
- P/E Ratio
- ACRV N/A
- DXR $68.18
- Revenue Growth
- ACRV N/A
- DXR N/A
- 52 Week Low
- ACRV $1.30
- DXR $6.55
- 52 Week High
- ACRV $11.51
- DXR $10.00
- Technical
- Relative Strength Index (RSI)
- ACRV 34.69
- DXR 40.41
- Support Level
- ACRV $1.30
- DXR $7.38
- Resistance Level
- ACRV $2.19
- DXR $8.19
- Average True Range (ATR)
- ACRV 0.32
- DXR 0.40
- MACD
- ACRV 0.10
- DXR -0.05
- Stochastic Oscillator
- ACRV 51.00
- DXR 17.65
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.